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Abstract
Purpose
To identify the protein profiles in vitreous associated with retinal fibrosis, angiogenesis, and
neurite formation in epiretinal fibrovascular membranes (FVMs) in patients with proliferative
diabetic retinopathy (PDR).
Methods
Vitreous samples of 5 non-diabetic control patients with vitreous debris and 7 patients with
PDR membranes were screened for 507 preselected proteins using the semi-quantitative
RayBio® L-series 507 antibody array. From this array, 60 proteins were selected for a cus-
tom quantitative antibody array (Raybiotech, Human Quantibody® array), analyzing 7 con-
trol patients, 8 PDR patients with FVMs, and 5 PDR patients without FVMs. Additionally,
mRNA levels of proteins of interest were measured in 10 PDR membranes and 11
idiopathic membranes and in retinal tissues and cells to identify possible sources of protein
production.
Results
Of the 507 proteins screened, 21 were found to be significantly elevated in PDR patients,
including neurogenic and angiogenic factors such as neuregulin 1 (NRG1), nerve growth
factor receptor (NGFR), placental growth factor (PlGF) and platelet derived growth factor
(PDGF). Angiopoietin-2 (Ang2) concentrations were strongly correlated to the degree of
fibrosis and the presence of FVMs in patients with PDR. Protein correlation analysis showed
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PDGF to be extensively co-regulated with other proteins, including thrombospondin-1 and
Ang2. mRNA levels of glial-derived and brain/derived neurotrophic factor (GDNF and
BDNF) were elevated in PDR membranes. These results were validated in a second study
of 52 vitreous samples of 32 PDR patients and 20 control patients.
Conclusions
This exploratory study reveals protein networks that potentially contribute to neurite out-
growth, angiogenesis and fibrosis in the formation of fibrovascular membranes in PDR. We
identified a possible role of Ang2 in fibrosis and the formation of FVMs, and of the neuro-
trophic factors NRG1, PDGF and GDNF in neurite growth that occurs in all FVMs in PDR.
Introduction
Proliferative diabetic retinopathy (PDR) is a serious ocular complication of diabetes and is
characterized by retinal neovascularization and microvascular leakage in response to chronic
ischemia. Although anti-VEGF therapy alongside pan-retinal photocoagulation has been
shown to reduce neovascularization and macular edema [1], response to anti-VEGF treatment
is heterogeneous [2]. Additionally, there have been concerns that anti-VEGF treatment may
temporarily increase fibrovascular membrane (FVM) formation and retinal traction [3–7].
Ultimately both retinal detachment and hemorrhages in PDR are the leading causes of perma-
nent vision loss or blindness in adults of working age [8,9]. Therefore, it is imperative that the
molecular pathways leading to FVM formation are better understood in order to identify
novel therapeutic targets.
Recently, it has also become clear that PDR is characterized not only by fibrovascular but
also by neuroglial pathology [10,11]. It was previously assumed that in PDR, the neurons of
the retina are incapable of proliferation, and that the total neural cell volume remains either
static, or is reduced due to apoptosis following diabetic damage [10]. Recently however, it has
been shown that PDR-associated FVMs contain neurite extensions growing alongside Mu¨ller
cells, a specialized type of retinal glia cell [12]. These neurites originate from rod photorecep-
tors and various populations of retinal ganglion cells [12–14]. New vessel growth is orches-
trated by chemoattractant and trophic factors derived from neurons [15] and Mu¨ller cells [16],
and Mu¨ller cells also serve as a scaffold for new vasculature [17]. Under these conditions, reti-
nal glial cells, macrophages, monocytes, hyalocytes (resident cells in the vitreous), fibroblasts,
pericytes and vascular endothelial cells will migrate and proliferate into the vitreous body,
hereby forming FVMs [18,19]. The cause and pathological implications of early neurite
recruitment in FVMs and their contribution to retinal angiogenesis and fibrosis are still
unknown.
FVM formation occurs secondary to secretion of cytokines and growth factors by the retina
in response to ischemia [4,20]. A number of cytokines and growth factors have been identified
in measurable quantities in the vitreous of PDR patients, and their levels correlated strongly
with PDR disease activity [21,22]. Among them, vascular endothelial growth factor (VEGF)
remains the growth factor that is most-frequently studied [23], although various other growth
factors such as transforming growth factor-ß (TGF- ß), hepatocyte growth factor (HGF),
plasma kallikrein and platelet-derived growth factor (PDGF) have also been implicated in
PDR [24–26]. Moreover, the balance between connective tissue growth factor (CTGF) and
VEGF is correlated with the degree of retinal fibrosis [4] and the angio-fibrotic switch. The
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large number of growth factors and cytokines that may be involved in PDR pathogenesis
necessitates the use of high throughput techniques to identify relevant proteins.
In the present study, we used a combination of semi-quantitative and quantitative antibody
arrays to screen over 500 proteins in the vitreous of PDR patients and control patients oper-
ated for vitreous floaters. We included a large series of angiogenic and neurogenic growth fac-
tors to identify those that are involved in PDR pathogenesis and thus are potential therapeutic
targets. In addition, we compared mRNA levels of the corresponding genes in FVMs of PDR
patients and idiopathic epiretinal membranes (ERMs, macular puckers of non-diabetic
patients) and various other retinal tissues to identify the possible sources of these proteins.
Materials and methods
Study population
For this study, 23 vitreous samples were used, including vitreous samples from PDR patients
(n = 16) and from patients with vitreous floaters (n = 7). In addition, 21 FVMs were collected
from patients with either PDR (n = 10) or non-diabetic patients with a macular pucker
(n = 11) who were operated by pars plana vitrectomy. Clinical variables were assessed by
trained ophthalmologists. The study was approved by the Medical Ethics Committees of the
Academic Medical Center and the VU University Medical Center, Amsterdam, The Nether-
lands. The study was conducted according to the tenets of the Declaration of Helsinki and
written consent was obtained from all patients.
Table 1 highlights clinical features of the 23 patients that were included in the study of pro-
teins in vitreous. There was no statistically significant difference in the average age of control
(58 years) and diabetic (52 years) patients (T-test, P = 0.27). Additionally, there was no differ-
ence in the gender ratio between both groups (Fischer’s exact test, P = 0.41). In total, 43% of
participants in the study were male and 57% were female. The majority of the PDR patients
received preoperative pan-retinal laser treatment (n = 14) and 9 out of 16 PDR patients
received preoperative anti-VEGF therapy with bevacizumab (Avastin; Genentech, San Fran-
cisco, California, USA).
Table 2 presents the clinical features of the 21 patients from whom membranes were har-
vested during pars plana vitrectomy. The patients where either non-diabetic and operated for
the removal of a macula pucker (n = 11), or suffering from PDR and operated for the removal
of FVMs (n = 10). PDR patients were on average younger (52 years) than control (71 year)
patients (T-test, P = 0.002). No difference in gender ratio between both groups was found
(Fischer’s exact test, P = 0.08). In total, 57% of the participants in the study were male and 43%
were female. Eight out of 10 PDR patients had received pan-retinal laser treatment and another
8 out of 10 patients were treated with bevacizumab at 3 days prior to surgery.
We repeated our analysis in an independent set of vitreous samples obtained by the Univer-
sity of Newcastle upon Tyne. A favorable ethical opinion for the collection of the samples was
obtained from the National Health Service (NHS) research ethics committee (South East Coast
—Surrey research ethics committee reference 12/LO/0130) and the collection carried out at
Sunderland Eye Infirmary under the sponsorship of City Hospitals Sunderland NHS founda-
tion trust. The study was conducted according to the tenets of the Declaration of Helsinki and
written consent was obtained from all patients. Fifty two vitreous samples of PDR patients
(n = 32) and of control patients without diabetes who had undergone vitrectomy for macular
hole or non-inflammatory vitreous opacities (n = 20) were included. Eighteen of the PDR
patients had fibrovascular membranes and 14 had no signs of fibrosis. PDR patients were on
average younger (56 years) than control patients (66 years) (t-test, P = 0.01). In total, 27% of the
52 patients were male and 73% were female with no difference in gender ratio between both
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groups (Fischer’s exact test, P = 0.13). None of the PDR patients had received pan-retinal laser
treatment or cataract surgery within the last 2 months, none had previous vitrectomy surgery
and none had undergone previous treatments with steroid therapy in the last year. Patients with
confounding retinovascular or other eye disease (e.g. retinal vein occlusion or glaucoma) and
patients who had received anti-VEGF therapy within the last 3 months were excluded.
Clinical measurements of PDR
The degree of fibrosis, activity of neovascularization, degree of hemorrhage, and presence and
type of diabetes, were obtained from pre-operative ophthalmic and ultrasound examinations.
Table 1. Clinical characteristics of patients whose vitreous samples were used for protein analysis with antibody arrays.
Case Status1 Ophthalmological
Status
Age Sex Hemorrhage2 Degree of
Fibrosis3
Degree of
Neovascularisation4
Laser Avastin Array5
1 CON Vitreal floaters 61 F 0 0 0 no no L+Q
2 CON Vitreal floaters 59 F 0 0 0 no no L+Q
3 CON Vitreal floaters 42 M 0 0 0 no no L+Q
4 CON Vitreal floaters 51 F 0 0 0 no no Q
5 CON Vitreal floaters 49 F 0 0 0 no no Q
6 CON Vitreal floaters 68 M 0 0 0 no no L+Q
7 CON Vitreal floaters 73 F 0 0 0 no no L+Q
8 DM2 PDR withoutFVM 54 F 1 0 0 yes no Q
9 DM2 PDR with FVM 44 M 3 3 2 yes no L+Q
10 DM2 PDR without FVM6 62 F 0 0 0 yes yes Q
11 DM2 PDR with FVM 56 M 2 2 2 yes yes L+Q
12 DM2 PDR with FVM 54 M 2 2 0 yes no Q
13 DM2 PDR with FVM 59 F 0 3 1 yes yes Q
14 DM2 PDR without FVM 63 M 1 0 2 yes yes Q
15 DM2 PDR without FVM 67 M 3 0 1 yes no Q
16 DM2 PDR with FVM 27 M 1 3 2 yes yes L
17 DM2 PDR with FVM 35 F 1 3 2 yes yes L
18 DM2
+ INS
PDR with FVM 55 F 2 2 1 yes no Q
19 DM2
+ INS
PDR with FVM 48 F 2 3 2 no yes L+Q
20 DM2
+ INS
PDR with FVM 53 F 0 3 2 yes no L+Q
21 DM2
+ INS
PDR without FVM 51 M 3 0 2 yes no Q
22 DM2
+ INS
PDR with FVM 51 F 1 2 2 yes yes Q
23 DM2
+ INS
PDR with FVM 57 M 0 3 2 no yes L
1 Diabetic status: CON, no diabetes; DM2, diabetes type 2; DM2 + INS, diabetes type 2 with insulin dependency.
2 Hemorrhage: 0, no hemorrhage; 1, mild hemorrhage; 2, moderate hemorrhage or heavy hemorrhage more than 2 months ago; 3, heavy hemorrhage
within 2 months.
3 Degree of fibrosis: 0, no evidence of fibrosis; 1, few pre-retinal membranes; 2, membranes with limited extension into the vitreous; 3, abundant white
membranes reaching into the vitreous body.
4 Degree of neovascularisation: 0, absent; 1, quiescent; 2, active.
5 Array used: L, L507 Array; Q, Quantibody Array.
6 Patient was operated for vitreomacular traction
https://doi.org/10.1371/journal.pone.0187304.t001
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Additionally, the patient files and per-operative observations, which were recorded using a
standardized form, were used. Fibrosis was graded as 0 when there was no fibrosis, as 1 when
there were a few pre-retinal membranes (limited as in macular pucker), as 2 when pre-retinal
membranes were present with limited extension into the vitreous, and as 3 when abundant
membranes reaching into the vitreous body were observed. Neovascularization was graded as
0 when absent, as 1 (quiescent) when only non-perfused vessels were present, and as 2 (active)
when perfused pre-retinal capillaries were present [27]. Degree of hemorrhage was graded as 0
when all media were clear and all fundus details were visible, as 1 when media were slightly
clouded but the fundus could still be examined, as 2 when the hemorrhage was moderate, or
heavy and more than 2 months ago, and as 3 when the hemorrhage was heavy and less than
two months ago.
Control tissue and cells
Control retinas from donor eyes were provided anonymously by the Corneabank Beverwijk
(http://www.eurotissuebank.nl/comeabank/), The Netherlands. In The Netherlands, the use of
donor material is provided for by a law named "Wet op Orgaan Donatie (WOD)". Following
this law, donors provide written informed consent for donation with an opt out for the use of
left-over material for related scientific research. Specific requirements for the use of left-over
Table 2. Clinical characteristics of patients whose fibrovascular membranes where used for mRNA analysis.
Case Status1 Ophthalmological Status Age Sex Hemorrhage2 Degree of Fibrosis3 Degree of Neovascularisation4 Laser Avastin
1 CON Pucker 84 F 0 1 0 no no
2 CON Pucker 66 F 0 1 0 no no
3 CON Pucker 72 M 0 1 0 no no
4 CON Pucker 79 M 0 1 0 no no
5 CON Pucker 62 F 0 1 0 no no
6 CON Pucker 73 F 0 1 0 no no
7 CON Pucker 70 M 0 1 0 no no
8 CON Pucker 66 F 0 1 0 no no
9 CON Pucker 80 F 0 1 0 no no
10 CON Pucker 63 F 0 1 0 no no
11 CON Pucker 69 M 0 1 0 no no
12 DM1 PDR 41 M 3 2 2 yes yes
13 DM1 PDR 59 M 2 1 2 yes no
14 DM1 PDR 43 M 3 1 2 yes yes
15 DM1 PDR 48 F 0 1 2 yes yes
16 DM2 PDR 25 M 3 3 2 no no
17 DM2 + INS PDR 48 F 2 3 2 no yes
18 DM2 + INS PDR 79 M 3 1 2 yes yes
19 DM2 + INS PDR 39 M 1 1 2 yes yes
20 DM2 + INS PDR 72 M 3 1 2 yes yes
21 DM2 + INS PDR 61 M 1 2 2 yes yes
1 Diabetic status: CON, no diabetes; DM2, diabetes type 2; DM2 + INS, diabetes type 2 with insulin dependency.
2 Hemorrhage: 0, no hemorrhage; 1, mild hemorrhage; 2, moderate hemorrhage or heavy hemorrhage more than 2 months ago; 3, heavy hemorrhage
within 2 months.
3 Degree of fibrosis: 0, no evidence of fibrosis; 1, few pre-retinal membranes; 2, membranes with limited extension into the vitreous; 3, abundant white
membranes reaching into the vitreous body.
4 Degree of neovascularisation: 0, absent; 1, quiescent; 2, active.
https://doi.org/10.1371/journal.pone.0187304.t002
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material originating from corneal grafting for scientific research have been described in an
additional document formulated by the Ministry of Health, Welfare, and Sport and the BIS
foundation (Eurotransplant; Leiden, July 21, 1995; 6714.ht). The present study was performed
in accordance with all requirements stated in the WOD and the relevant document and in
accordance with these regulations approval of the local medical ethics committee was not
required as the data were analyzed anonymously.
Human primary retinal pigment epithelial cells were also obtained from donor eyes, with a
post mortem time of less than 15 hours, as described previously [28]. Human primary retinal
endothelial cells and pericytes were obtained from donor eyes (up to 24 hours post mortem) as
described for bovine retinas [29]. Endothelial cells were cultured in complete EBM-2 medium
(Lonza, Breda, The Netherlands) with 5% human serum. For glial cells a human astrocytoma
cell line, U-373 MG (Uppsala) (Sigma-Aldrich, Zwijndrecht, The Netherlands) was used. RNA
from blood was obtained as described previously [30].
Vitreous protein quantitation
Vitreous samples of 7 PDR patients with FVMs and of 5 control patients were measured using
a biotin label-based human antibody array (Human Antibody L-series 507 Array; RayBiotech,
Norcross, GA, USA) to screen for potential proteins of interest. The array was performed in
accordance with the manufacturer’s instructions. In brief, vitreous samples were centrifuged
for 15 min at 14,000 g at 4˚C. Supernatant was collected and dialyzed with PBS overnight at
4˚C. After determination of protein concentrations, the appropriate amount of biotin was
added and samples were again dialyzed with PBS overnight at 4˚C. Samples were then hybrid-
ized to the arrays overnight at 4˚C with gentle shaking. Biotinylated proteins captured by the
membrane-bound antibodies were detected by incubation with HRP-streptavidin and analysis
was performed by an Agilent laser scanner (Agilent Technologies, Palo Alto, CA, USA). Spot
intensities were quantified with ScanAlyze software (Michael Eisen, http://rana.lbl.gov/
EisenSoftware.htm) and mean signal and median background values were applied in subse-
quent calculations.
Sixty proteins of interest (based on results of the L507 array and relevant literature) were
selected for further quantitative analysis. Quantitation was achieved using a customizable
array-based multiplex immunoassay (RayBiotech, Human Quantibody1 array) in accordance
with the manufacturer’s instructions. Standard curves for each protein were generated and the
lower limit of detection (LOD) was calculated based on the average and standard deviation of
four negative controls (average + 2x standard deviation). Proteins that were undetectable in
more than half of the samples were deemed to be below the LOD.
Correlation network construction
The correlation network was constructed in the statistical package ‘R’ (version 3.2.3) (https://
www.R-project.org) using the igraph package (version 1.0.1) (igraph.org). First, Pearson corre-
lations between Quantibody protein profiles over all samples were calculated for all pairs of
proteins. Subsequently, the proteins were presented in a correlation network [27] in which the
nodes represent proteins and the interconnecting lines represent the correlation between the
proteins. We discarded all correlations that were lower than 0.7 and removed all unconnected
proteins.
RNA isolation and mRNA quantification
Fibrous tissue was removed during surgery, placed in 250 μL TRIzol reagent (Life Technolo-
gies, Carlsbad, CA, USA) and stored at -80˚C until further processing. Membranes were then
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homogenized using a pestle and vortexed. RNA from ERMs was extracted and quantified using
techniques described previously [28]. Total RNA yields were measured using a NanoDrop
(ND1000 Spectrophotometer; NanoDrop Technologies, Wilmington, DE, USA) and RNA qual-
ity was assessed using an Experion™ Automated Electrophoresis System (Bio-Rad, Hercules,
CA, USA). For all samples, RNA quality indicator (RQI) values ranged between 6.5 and 8.5.
A 1-μg aliquot of total RNA was treated with DNAse I (Amplification Grade; Invitrogen)
and reverse transcribed into first strand cDNA using the Maxima1 First Strand cDNA Syn-
thesis Kit (Thermo Scientific, Roskilde, Denmark). Real-time quantitative PCR was performed
on 20x diluted cDNA samples using a CFX96 system (Bio-Rad, Hercules, CA) as described
previously [31].
Primer details are listed in S2 Table. The specificity of the primers was confirmed by NCBI
BLAST. The presence of a single PCR product was verified by both the presence of a single
melting temperature peak and detection of a single band of the expected size on 3% agarose
gel. Non-template controls were included to verify the method and the specificity of the prim-
ers. Normalization of data was performed with global mean normalization [32].
Statistical analysis
Values of vitreous proteins are reported as a mean (pg/ml) ± standard deviation. Univariable
analysis with two-tailed T-tests assuming unequal variance were performed to identify individ-
ual proteins significantly associated with PDR. For all statistical analyses a P value< 0.05 was
considered to indicate statistically significant differences.
Results
Detection of vitreous proteins
The L507 array allowed us to screen the vitreous for presence of 507 proteins in PDR patients
with FVMs relative to control patients with floaters. 453 proteins were shown to have a higher
and 54 proteins had a lower concentrations in vitreous of PDR eyes. Only 55 of the proteins
were significantly higher in concentration in PDR patients, whereas none of the proteins were
significantly lower in concentration in PDR patients (two-tailed Welch’s t-test). Fifty three
proteins had concentrations in the vitreous of PDR patients more than 2-fold higher than con-
trols, while 25 proteins had a 10-fold higher concentration (S1 Table).
Quantitation of vitreous proteins
On the basis of the results of the L507 array and relevant literature, we designed a custom
quantibody array containing antibodies for the detection of 60 proteins in 20 samples (13 PDR
and 7 controls). Although more expensive, the advantage of the quantibody array is that actual
protein concentrations rather than relative yields of protein can be measured. Of the 60 pro-
teins screened, 20 had concentrations below the LOD (defined as>50% of samples below
detection limit) and were excluded from further analysis (AR, b-NGF, BDNF, COCO, E-Selec-
tin, GDNF, ICAM3, IGF1R, IGF2, Insulin, Insulin R, NT3, NT4, PDGF-Ra, PDGF-Rb, Prolac-
tin, TARC, TGFβ1, TPO and XEDAR). For the other 40 proteins, occasional samples that were
below the LOD were approximated as the LOD/
p
2 [33]. Four proteins showed concentrations
above the highest standards (Adiponectin, IGFBP6, NrCAM and TIMP-1).
The results of the quantibody array and the lower limits of detection are presented in
Table 3. Twenty-one proteins were significantly upregulated in PDR patients (Welch’s T-test)
and are highlighted in bold. In addition, 14 of the proteins exhibited a larger than 3-fold rise in
concentration and are highlighted in bold. In a second independent study group of PDR
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Table 3. Protein concentrations in vitreous of control and PDR patients. Protein concentrations were determined by Quantibody arrays in patients with
vitreal floaters (CON) and patients with proliferative diabetic retinopathy (PDR) that underwent vitreoretinal surgery.
CON PDR
LOD mean SD min max mean SD min max Fold Change P-value
Adiponectin* 5.5 9680.0 4869.9 2116.3 17181.5 38271.7 21622.7 6359.8 71881.8 3.95 <0.001
ANG-1 5.4 95.1 28.0 57.0 137.8 259.6 240.4 69.4 863.9 2.73 0.031
ANG-2 5.1 93.5 52.9 28.9 161.0 1802.4 2979.4 117.8 11369.4 19.28 0.061
AR 8.2 BDL BDL
BDNF 1.0 BDL BDL
bFGF 32.5 117.0 236.8 23.0 653.7 45.2 19.6 23.0 80.0 0.39 0.454
BMP-2 1.7 59.2 11.5 44.6 73.4 95.9 51.5 27.7 202.6 1.62 0.028
BMP-5 148.6 240.7 111.3 105.1 396.9 281.8 106.4 105.1 513.1 1.17 0.439
b-NGF 2.9 BDL BDL
COCO 418.2 BDL BDL
DcR3 242.7 202.1 52.1 171.6 282.1 656.5 655.2 171.6 2487.7 3.25 0.028
ErbB3 13.0 154.5 24.5 126.5 186.6 179.4 98.2 9.2 403.9 1.16 0.401
E-Selectin 50.2 BDL BDL
Galectin-3 32.5 162.9 284.2 23.0 798.7 353.1 497.5 23.0 1579.9 2.17 0.291
GDF-15 0.8 370.7 273.1 48.1 880.7 975.7 425.8 172.8 1645.4 2.63 0.001
GDNF 3.0 BDL BDL
GH 29.0 34.1 20.5 20.5 75.2 77.5 53.0 20.5 177.8 2.28 0.018
HGF 4.3 2500.6 1062.3 1618.6 4418.0 7967.1 2151.6 2752.1 10711.5 3.19 <0.001
ICAM-1 76.4 696.0 1031.4 54.0 2707.0 3762.4 3531.0 696.9 13167.3 5.41 0.011
ICAM-3 24.7 BDL BDL
IGFBP-1 4.3 222.5 242.9 38.6 726.1 2210.9 2132.1 207.7 7383.2 9.94 0.006
IGFBP-2 41.5 16751.2 7003.4 7562.7 30992.2 24718.9 9332.7 13573.6 42543.5 1.48 0.047
IGFBP-3 114.1 1043.7 704.0 319.4 2053.4 19596.4 11034.1 2595.4 37544.3 18.78 <0.001
IGFBP-4 539.2 3463.8 1293.0 2009.4 5910.7 3471.7 1488.8 1156.9 6029.0 1.00 0.990
IGFBP-5 115.4 234.3 125.6 81.6 393.4 389.6 366.1 81.6 1570.1 1.66 0.185
IGFBP-6* 68.3 27483.8 8803.2 22349.7 47174.6 33899.1 10489.7 21769.8 55469.0 1.23 0.168
IGF-I 27.0 51.8 41.1 19.1 129.4 62.3 40.2 19.1 151.5 1.20 0.594
IGF-I R 48.6 BDL BDL
IGF-II 41.4 BDL BDL
IGF-II R 18.4 199.2 47.5 148.0 266.4 208.7 190.9 27.2 770.8 1.05 0.867
Insulin 20.1 BDL BDL
Insulin R 3,115.9 BDL BDL
NCAM-1 104.1 17561.3 8210.6 5251.9 28434.0 17835.7 9907.3 6488.9 37545.7 1.02 0.948
NGF R 10.3 41.3 27.4 7.3 78.5 74.7 21.7 40.2 105.6 1.81 0.019
Notch-1 2.1 21.9 16.4 12.6 58.3 17.4 18.2 1.5 62.7 0.80 0.590
NOV 5.8 1836.0 458.4 1202.5 2740.6 3206.6 942.9 1627.7 5509.0 1.75 <0.001
NrCAM* 5.0 4872.9 1914.6 2185.5 7215.7 6082.5 3285.2 715.4 12610.8 1.25 0.313
NRG1-b1 10.8 11.9 4.8 7.6 19.9 36.9 27.5 7.6 69.7 3.10 0.007
NT-3 12.1 BDL BDL
NT-4 5.3 BDL BDL
PDGF Ra 1,170.8 BDL BDL
PDGF Rb 10.8 BDL BDL
PDGF-AA 2.0 99.1 86.8 9.6 263.3 602.2 556.6 91.8 1827.7 6.08 0.007
PDGF-AB 5.0 6.6 1.6 3.5 8.3 16.9 16.2 5.5 67.5 2.54 0.042
PDGF-BB 0.4 0.7 0.5 0.3 1.3 2.9 2.7 0.6 9.3 4.03 0.015
(Continued )
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patients (n = 32) and controls (n = 20) from the University of Newcastle upon Tyne, we mea-
sured protein levels of 5 of these proteins (Ang2, NRG1β1, PDGF-AA, PlGF and VEGF). The
fold changes between PDR patients and controls were comparable with those of the first study
group and the differences were statistically significant, except for NRG1β1 (S3 Table).
Next, we attempted to identify differences in protein concentrations between PDR patients
with and without FVMs. Vitreous samples were divided into control, PDR patients without
membranes and PDR patients with membranes. A significant upregulation of Ang2 in PDR
+FVM patients compared to PDR-FVM patients was found (Kruskal-Wallis + Mann-Whitney
U test) (Fig 1). Ang2 protein levels were log10 transformed to obtain a normal distribution. A
similar trend for Ang2 was observed in the independent study group (S1 Fig). No statistically
significant differences in concentrations of the other proteins were found in PDR patients with
or without FVMs.
Correlations between vitreous protein concentrations and clinical
features of PDR
Correlations between vitreous protein concentrations in PDR patients and clinical features of
fibrosis, neovascularization and vitreous hemorrhage were assessed using Spearman’s rank
correlation coefficients. Moderate correlations were defined as coefficients between 0.40 and
0.59 and strong correlations between 0.60–0.79. PDGF-AA, Ang2 and PlGF showed a strong
correlation with the degree of fibrosis (R2 = 0.638, 0.632 and 0.597, respectively), whereas
IGF-II R showed a strongly negative correlation (R2 = -0.617). Additionally, IGFBP-6, GDF-15
and Ang1 were strongly correlated with neovascularization (R2 = 0.629, 0.623 and 0.599,
respectively). The degree of vitreous hemorrhage was negatively correlated with NrCAM,
NCAM-1 and DcR3 (R2 = 0.709, 0.669 and 0.563, respectively).
Table 3. (Continued)
CON PDR
LOD mean SD min max mean SD min max Fold Change P-value
PIGF* 2.5 1.8 0.0 1.8 1.8 102.8 134.5 1.8 467.4 57.30 0.019
Prolactin 151.7 BDL BDL
TARC 1.7 BDL BDL
TGFb1 151.4 BDL BDL
TGF-b2 7.1 30.3 14.1 13.0 43.9 48.9 56.7 5.0 184.7 1.61 0.281
Thrombospondin-1 215.0 980.3 1650.2 152.0 4645.7 10116.4 10082.6 499.9 34455.3 10.32 0.007
TIMP-1* 13.4 60145.6 19198.7 41110.6 88938.0 61745.9 9704.1 47592.0 82709.5 1.03 0.842
TIMP-4 6.5 395.0 333.7 142.0 1054.3 611.8 282.4 196.5 1069.2 1.55 0.173
TPO 139.9 BDL BDL
Ubiquitin+1 136.8 261.9 197.4 96.7 578.9 897.7 390.9 271.1 1465.3 3.43 <0.001
VCAM-1 794.5 7383.1 7964.7 561.8 23677.8 8143.9 5254.2 2198.5 22644.2 1.10 0.825
VEGF 10.7 23.5 42.2 7.6 119.2 1208.1 1528.2 7.6 5038.6 51.40 0.016
WIF-1 19.5 11133.9 2970.5 8184.8 15679.3 9207.2 3063.2 4362.8 13964.5 0.83 0.195
WISP-1 68.6 176.1 98.6 48.5 293.8 191.5 121.9 48.5 499.5 1.09 0.763
XEDAR 3.3 BDL BDL
Data are presented in pg/mL ± SD with min and max values. BDL, below limit of detection (LOD). Unpaired t-test with Welch’s correction was used to
assess statistical differences between PDR and control patients. Fold changes higher than 3-fold and significant differences (P < 0.05) are indicated in bold.
*Adiponectin, levels in PDR patients above the highest standards; IGFBP6, NrCAM, TIMP-1, all levels above the highest standards; PlGF, all control levels
were below LOD and set at LOD/p2.
https://doi.org/10.1371/journal.pone.0187304.t003
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Effects of bevacizumab on protein concentrations
Six of the PDR patients had been treated by intravitreous injection with bevacizumab 3 days
prior to surgery. We investigated whether the use of bevacizumab had effects on the concentra-
tions of proteins other than VEGF. Whereas VEGF concentrations were almost completely
downregulated by bevacizumab, concentrations of PlGF (a family member of VEGF) were not
significantly affected (Fig 2). IGF1 concentrations, however, were significantly higher in
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Fig 1. Ang2 protein is increased in vitreous of PDR patients with FVMs. Protein levels of Ang2, as
detected by Quantibody arrays, were log10 transformed to obtain a normal distribution. Differences between
groups were analyzed by a Student’s t-test. CON, non-diabetic control patients; PDR–FVM, PDR patients
without FVMs; PDR + FVM, PDR patients with FVMs. The lines represent the geometric means.
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Fig 2. Effect of anti-VEGF therapy on protein levels. Samples were divided in three groups: CON, non-diabetic control patients; PDR—B, PDR patients
that did not receive bevacizumab; PDR + B, PDR patients that received bevacizumab. Differences between groups were analyzed with an unpaired t test
with Welch’s correction. Lines represent mean values.
https://doi.org/10.1371/journal.pone.0187304.g002
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bevacizumab-treated eyes (p = 0.0155). Significant effects of bevacizumab on other proteins
were not observed.
Correlations between proteins
We investigated whether proteins were co-regulated and analyzed this by a pairwise compari-
son of proteins (Fig 3). Visual inspection revealed 3 groups of co-expressed proteins. The larg-
est group contained the most interactions, showing co-expression of various proteins centered
around a PDGF axis, consisting of the PDGF-AA, AB and BB subunits. In another group, co-
regulation was found between neuronal cell adhesion molecule (NrCAM) and neural cell
adhesion molecule (NCAM). Weaker associations were found in the third group between
growth differentiation factor 15 (GDF15), nephroblastoma overexpressed (NOV), hepatocyte
growth factor (HGF), and insulin-like growth factor binding protein 3 (IGFBP3).
Fig 3. Coregulation of proteins. Pearson correlations between Quantibody protein profiles over all samples
as calculated for all pairs of proteins. The proteins are presented in a correlation network in which the nodes
represent proteins and the interconnecting lines represent the correlation between the proteins. The thickness
of the lines represent the strength of the correlation. All correlations <0.7 and disconnected proteins were
removed.
https://doi.org/10.1371/journal.pone.0187304.g003
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Gene expression in idiopathic and PDR-associated membranes
In order to identify possible cellular or tissue sources of the proteins in the vitreous of PDR
patients, we determined gene expression in FVMs and compared these data to gene expression
in blood cells from diabetic patients, control retina tissue, retinal pigment epithelial cells
(RPE), human retinal endothelial cells (HRECs), human retinal pericytes (HRPCs) and human
glial cells (Table 4). In total 11 idiopathic ERMs, and 10 PDR membranes were analyzed.
In accordance with protein concentrations found in the vitreous of PDR patients, 5 genes
were found to be consistently expressed in all PDR membranes (GDF15, IGFBP3, THBS1,
TIMP1 and VEGFA). In addition, BDNF and GDNF were found to be expressed in all idio-
pathic and 9 of the 10 PDR membranes (Table 4), even though protein concentrations of these
respective proteins in the vitreous were below the LOD (Table 3).
Increased vitreous protein concentrations may be due to either increased local production
or due to leakage from the vasculature. Despite showing elevated vitreous concentrations,
angiogenic growth factors such as adiponectin, PDGFA and PDGFBmRNAs were hardly, or
Table 4. Gene expression in membranes, retinal tissues and cells, and blood.
n = 11 n = 10 Relative expression
Gene iERM PDR iERM PDR* Retina RPE Glial cells HRECs HRPCs Blood
ADIPOQ 0 0 0 0 0 0 0 0 0 2
ANGPT2 7 9 30 135 150 0 4 22 0 13
BDNF 11 9 182 72 117 387 475 1337 550 1015
bNGF 8 6 7 32 13 394 134 30 210 687
GDF15 11 10 35 48 9 14 80 34 411 487
GDNF 11 10 12962 41091 0 0 156 177 0 512
HGF 10 8 136 359 268 3 0 72 857 153
ICAM1 11 9 90 224 780 545 24 279 75 1394
IGFBP1 7 7 26 47 0 1 4 721 7 56
IGFBP3 11 10 4179 2726 282 10095 317 3384 5234 257
NCAM1 10 8 810 392 1006 11 176 241 0 19
NGFR 10 8 1295 1933 1302 0 27 0 0 0
NOV 4 5 5 10 38 151 0 10 5 163
NRG1 10 5 36 12 47 99 649 318 33 17
NRG2 7 6 26 18 69 1 189 5 2 0
NRN1 11 9 288 392 3652 0 1628 169 0 979
NTF3 4 4 9 6 36 940 19 80 0.2 711
NTF4 0 0 0 0 0 0 101 3 5 773
PDGFA 0 2 0 4 0 0 11 0 0 17
PDGFB 0 0 0 0 0 0.5 3 14 0 29
PGF 9 7 242 47 71 0 10 15 0 5913
THBS1 11 10 2479 2011 2 610 88481 2749 7989 1132
TIMP1 11 10 6544 10088 11366 90200 40299 361760 59631 12807
VEGFA 11 10 4434 907 8879 18 8369 165 188 507
Left side (iERM, PDR): number of membranes in which gene expression is detected. Right side (Relative expression): abundance of gene expression in
arbitrary units. iERM, idiopathic epiretinal membrane; PDR, epiretinal membrane from PDR patient; Retina, whole retina of non-diabetic donor eye; RPE,
primary retinal pigment epithelial cells; Glial cells, U373 cell line; HRECs, human primary retinal endothelial cells; HRPCs, human primary retinal pericytes;
Blood, pooled whole blood from patients with diabetic macular edema. Underlined values show significant difference in gene expression levels between
PDR and iERM membranes (P < 0.05).
https://doi.org/10.1371/journal.pone.0187304.t004
Identification of proteins involved in PDR membrane formation
PLOS ONE | https://doi.org/10.1371/journal.pone.0187304 November 2, 2017 12 / 21
not at all, found in membrane tissues. In other ocular tissues studied, adiponectin was only
detected in blood cells and not in any of the ocular tissues including FVMs, whereas PDGFA
was expressed in white blood cells and glial cells and PDGFBwas expressed in white blood
cells, RPE cells, glial cells and HRECs. Since PDGF concentrations in the vitreous of PDR
patients were lower than the concentrations of PDGF reported in the plasma of both diabetic
patients [34] and healthy volunteers [35], PDGFA is most likely derived from blood, whereas
PDGFB is probably synthesized by either RPE, HREC or glial cells. TIMP1, which showed the
highest vitreous protein concentrations, also showed the highest abundance in mRNA levels in
all tissues and cells, with HRECs being the major source.
When considering differences in mRNA expression levels between non-diabetic ERMs and
PDR membranes, a few observations stand out: expression levels of ANGPT2were 4.6-fold
higher in PDR membranes as compared to non-diabetic ERMs (Table 4; Fig 4), which is in
agreement with the elevated vitreous protein concentrations in PDR patients (Table 3). Con-
versely, gene expression levels of NRG1, PGF and VEGFA were strikingly lower in PDR mem-
branes when compared to controls (Table 4; Fig 4), whereas proteins concentrations in the
vitreous of PDR patients were increased (Table 3). In addition, mRNA levels of connective tis-
sue growth factor (CTGF), a marker of fibrosis [4], IGFBP3 and vimentin (VIM), a highly
abundant glial cell marker in ERMs, were comparable between non-diabetic ERMs and PDR
membranes (Fig 4).
Discussion
In the present study, vitreous samples were screened for 507 proteins, including various neural
and glial growth factors, leading to the identification of 55 vitreous proteins elevated in PDR.
A search in the Embase and Pubmed databases indicates that 8 of these proteins (BMP2,
DcR3, GDF15, IGFBP4, NGFR, NOV, NRG1β1, UBB+1) were not previously reported to be
associated with PDR.
A serious sight threatening complication of PDR is the formation of FVMs, which may
result in retinal traction and retinal detachment. An initial step in the formation of these
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Fig 4. mRNA levels in idiopathic and PDR membranes. Transcript levels of genes were quantified by real-time quantitative PCR. Differences
between groups were analyzed by a Student’s t-test. Lines represent mean values.
https://doi.org/10.1371/journal.pone.0187304.g004
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membranes may be neurite outgrowth from neurons and Mu¨ller cells, which not only secrete
neurotrophic and pro-angiogenic growth factors, but may also serve as a template for the
growth of other cell types and new blood vessels [4,18,19]. We identified Ang2 as being the
most strongly correlated protein to the degree of fibrosis and the presence of FVMs in patients
with PDR. Furthermore, the PDGFs seem to play a role in fibrosis and in neurite outgrowth as
well, based on our observations in all membranes.
Proteins related to neurite outgrowth
Many of the tested neurotrophins, such as NT3, NT4, bNGF, BDNF and GDNF were below
the LOD in both control samples and PDR samples, suggesting that these proteins are not
involved in retinal-vitreous neurite formation. Other studies confirmed the absence of bNGF
and BDNF [36], but showed detectable levels of NT3 and NT4 [36] and GDNF [37], suggesting
differences in sensitivity or specificity of the detection methods. While GDNF was found to be
undetectable in the vitreous of PDR patients, we did find active mRNA transcription of GDNF
in all PDR-associated membranes, as well as in the non-diabetic macular puckers. Further
studies to clarify the possible role that GDNF may play in retinal neurite growth are
warranted.
Other neurotrophic factors such as Neuregulin1/Heregulin1-b1 (NRG-1) exhibited a>3
fold upregulation in the vitreous of PDR patients, implicating their possible involvement in
neurite outgrowth. Indeed, previous reports show that NRG1 can elicit neurite outgrowth in
dorsal root ganglia explants [38] and developing rat retina [39]. Additionally, there may be
increased sensitivity for neurotrophic factors as evidenced by the elevated concentrations of
nerve growth factor receptor (NGFR) found in the vitreous of PDR patients. However, in the
independent study group, the increased NRG1β1 protein levels were not confirmed, thus mak-
ing the involvement of NRG1β1 in neurite outgrowth dubious.
Another possibility is that PDGF drives neurite growth, in addition to its angiogenic effects
[40]. Indeed, PDGF has been shown to induce neuronal [41,42] and Mu¨ller cell proliferation
in vitro [43], and outgrowth of neurites in primary rat brain cultures [44]. Additionally, trans-
genic mouse models overexpressing PDGFA have increased retinal glial cell proliferation [45],
which can in turn drive neurite outgrowth via purinergic G protein-coupled receptor activa-
tion [46].
A role for PDGFs in fibrosis
Although PDGF is known to be a strong angiogenic stimulus, we also found a strong correla-
tion between PDGFAA concentrations and retinal fibrosis. In addition, PDGF was correlated
with a number of other proteins known to be involved in fibrosis and neovascularization such
as angiopoietin-1 (Ang1, ANGPT1) and -2 (Ang2, ANGPT2), PlGF and TGFβ [47]. This raises
the possibility that PDGF may be one of the driving forces behind pathological angiogenesis
and fibrosis in patients with PDR. Recent studies have shown that PDGF has a role in the pro-
duction of FVMs in patients with a related condition, proliferative vitreoretinopathy (reviewed
by Lei et al., 2010) [48]. In this condition, in contrast to PDR, fibrosis rather than a mixture of
angiogenesis and fibrosis is the main pathological process.
Angiopoietins
Ang1 and Ang2 are known to exert their biological effects by competitively binding to endo-
thelial cell-specific tyrosine kinase with immunoglobulin and epidermal growth factor homol-
ogy domains 2 (Tie-2) receptors [49]. The angiopoietin/Tie2 system is a context-dependent
system with opposing effects. Binding of Ang1 leads to Tie2 phosphorylation and endothelial
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cell stabilization, but Ang2 binding leads to robust angiogenesis in the presence of VEGF [50].
A decreased ratio of Ang1 and Ang2 seems to be a critical switch for the development of vascu-
lar pathology, including blood-retinal barrier breakdown [51] and pericyte migration [52].
Here, we confirm reports that PDR is characterized by a disturbed balance of Ang1 and Ang2,
since the concentrations of Ang2 were found to be increased almost 20-fold in PDR, whereas
Ang1 concentrations only increased 3-fold.
In addition, Ang2 was found to be correlated to the degree of retinal fibrosis. ANGPT2 gene
expression was found in all PDR membranes and in the majority of non-diabetic ERMs. Fur-
thermore, vitreous samples of PDR with FVMs had increased concentrations of Ang2 com-
pared to PDR without FVMs. This could be accounted for by increased production of Ang2
from highly activated FVM endothelial cells [53]. It seems that, in addition to playing a role in
active angiogenesis [50,54], Ang2 may well be involved in retinal fibrosis in PDR. This is sup-
ported by increased intravitreal Ang2 concentrations related to rhegmatogenous retinal
detachment [55] and formation of FVMs in patients with retinopathy of prematurity [56].
Also, Ang2 was shown to be causative in the formation of liver fibrosis in rats [57] and cardiac
fibrosis in db/db mice [58].
Thrombospondin
We observed high protein concentrations of thrombospondin-1 in vitreous of PDR patients,
10-fold higher than in control vitreous samples. In conjunction, gene expression of THBS1
was observed in all membranes in comparable quantities in non-diabetic ERMs and PDR
membranes. Thrombospondin-1 is a matricellular glycoprotein that has anti-angiogenic prop-
erties and is involved in wound healing and fibrosis in the eye [59]. A possible mechanism is
the activation of latent TGFβ, either directly [60], or indirectly by induction of MMP-2 and
MMP-9 [61,62]. It is detected as an abundant protein on platelets and is secreted by endothe-
lial cells, fibroblasts, smooth muscle cells, and many other cells of the retina, including glial
cells (summarized by Masli et al., 2014 [59]). Indeed, we observed high transcript levels in
these cell types, especially in glial cells, endothelial cells and pericytes. Thrombospondin-1 pro-
tein in vitreous has not been widely studied thus far. One study reports undetectable levels
[63], whereas another study reports detectable levels by western blotting in human postmor-
tem donor eyes and rat eyes [64]. In contrast to our results, vitreous samples from diabetic rats
showed decreased thrombospondin-1 levels as compared to controls in the prior study. More
research is needed to find out whether these differences are caused by technical or species-
dependent factors. Considering the contribution to anti-angiogenesis, thrombospondin-1 may
be upregulated in response to pro-angiogenic factors to counteract and balance the angiogenic
switch in PDR. Interestingly, thrombospondin-1 and Ang2 were both clustered around the
PDGF-axis in the correlation network analysis, which suggests that these proteins are co-regu-
lated within our samples. This may mean that PDGFs, thrombospondin-1 and Ang2 work
together in the formation of FVMs in PDR. More research is needed to clarify the relationship
between these proteins.
IGFBPs
Two insulin-like growth factor binding proteins, IGFBP-1 and -3, stood out with respect to
their increased vitreous protein concentrations in PDR patients as compared to controls, with
an increase of 10- and 19-fold respectively. Of these, IGFBP3 mRNA was also abundantly
expressed in non-diabetic ERMs and PDR membranes and several control tissues, with RPE
cells showing the most abundant expression. Others have reported increased IGFBP1 [65] and
IGFBP3 [66,67] levels in the vitreous of PDR patients in the same range. IGFBPs bind IGFs in
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the serum to protect them from degradation and increase their bioavailability [68]. IGFBP3 is
described to have both pro-angiogenic and anti-angiogenic effects, probably dependent on the
context and the presence of certain other growth factors. IGF1- and VEGF-induced prolifera-
tion and survival of human umbilical vein endothelial cells were both inhibited by IGFBP3
[69], whereas IGFBP3 supplementation to mouse Matrigel implants increased vascular
ingrowth as compared to control animals [70]. In addition, IGFBP3 has been reported to be a
protector of blood-retinal barrier breakdown and a stimulator of vasorelaxation by mediating
NO levels [71]. Because of complex interactions with other serum proteins, the mechanism of
IGFBP3 involvement in the pathophysiology of PDR may be difficult to unravel. On the other
hand, IGFBP3 levels may serve as a useful biomarker of disease severity in PDR.
Effect of bevacizumab
Because some of the patients received bevacizumab before surgery, we were able to analyze the
effects of anti-VEGF treatment on protein concentrations. There have been concerns that inhi-
bition of VEGF may upregulate other pro-angiogenic proteins, which could explain resistance
to anti-VEGF therapy. One such protein is PlGF, a family member of VEGF, which has been
reported to be iatrogenically upregulated by anti-VEGF therapy [72,73]. In the present study,
we did not observe an upregulation on PlGF following bevacizumab treatment, whereas con-
centrations of IGF1 were significantly upregulated. These observations need to be carefully
interpreted since the number of patients was rather low and need further investigations. IGF1
upregulation may be a reaction to the absence of VEGF, since IGF1 is known to induce VEGF
synthesis [74]. It is worth noting that mRNA levels of VEGF were also significantly lower in
the membranes of PDR patients as compared to controls. It is possible that this may due to the
anti-VEGF treatment since all except two of the PDR patients received bevacizumab before
surgery. It has previously been reported that anti-VEGF treatment may target endogenous
VEGF levels, which is known to regulate its own transcription through VEGFR2 [75]. Besides
VEGF, concentrations of 3 other protein were decreased in ERMs of PDR patients as com-
pared to controls: PlGF, NRG1 and BDNF. Decreased PlGF may be explained by the transcrip-
tional regulation by VEGF in microvascular endothelial cells [76], but the relation of VEGF
with NRG1 and BDNF is less clear. In one study VEGF was found to work upstream from
BDNF produced by endothelial cells in neurogenesis in songbirds [77] and in another study
BDNF was found to promote the expression of NRG1 in neurons [78]. These observations
warrant further investigation on larger patient groups.
Limitations of the study
This study was limited by the small number of samples that we were able to obtain. Future
studies using a larger patient population will enhance the statistical power of the correlations
obtained in this study. Additionally, the use of a non-proliferative diabetic group of patients
will allow more accurate assessment which growth factors are specific to PDR.
The cross-sectional acquisition of vitreous fluid only allowed protein measurements to be
taken at a single time point in the course of disease. This makes inferences regarding causality
difficult since the sequence of fluctuations in protein concentrations over time could not be
obtained. Furthermore, we were unable to distinguish between proteins produced in the retina
and proteins derived from the blood via a compromised blood-retina barrier or vitreous hem-
orrhage [79].
Our selection of proteins analyzed in the antibody arrays was limited by commercial avail-
ability. In this way, we regret that it was not possible to include measurements of CTGF, a pro-
tein previously reported to be integral in the relationship between retinal fibrosis and
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angiogenesis [4]. Further studies investigating the changes, origin, and sites of action of the
proteins identified here will yield further insight into the pathophysiology of FVM formation
in PDR.
Conclusions
In conclusion, we found 8 novel proteins in the vitreous of PDR patients, as well as novel cor-
relations between vitreous proteins and retinal fibrosis and angiogenesis. Ang2 was not only
strongly related to the degree of fibrosis, but was also related to the occurrence of FVMs, sug-
gesting that it may have a causative role in the formation of these membranes. In addition, the
elevated concentrations of the neurotrophic factors NRG1 and PDGF in vitreous, and high
gene expression levels of GDNF and BDNF in PDR membranes present potential proteins
responsible for the retinal neurite growth that is displayed in all FVMs. The large amount of
proteins that have been screened in our study may serve as a basis for more detailed analysis in
larger study groups, eventually leading to a better understanding of molecular mechanisms of
PDR pathology.
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